EFM
TGTX icon

E Fund Management’s TG Therapeutics TGTX Stock Holding History

E Fund Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Sell
9,040
-11,666
-56% -$477K 0.01% 269
2026
Q1 		$688K Buy
+20,706
New +$617K 0.02% 221
2025
Q2 		$756K Buy
21,009
+4,013
+24% +$149K 0.04% 191
2025
Q1 		$670K Sell
16,996
-6,558
-28% -$221K 0.03% 197
2024
Q4 		$709K Buy
23,554
+1,711
+8% +$49.1K 0.04% 187
2024
Q3 		$511K Buy
21,843
+1,378
+7% +$30.1K 0.03% 193
2024
Q2 		$364K Sell
20,465
-5,361
-21% -$85.5K 0.02% 208
2024
Q1 		$393K Sell
25,826
-4,727
-15% -$75.3K 0.02% 226
2023
Q4 		$522K Sell
30,553
-13,457
-31% -$156K 0.03% 154
2023
Q3 		$368K Buy
44,010
+27,744
+171% +$387K 0.03% 181
2023
Q2 		$404K Sell
16,266
-11,162
-41% -$288K 0.03% 164
2023
Q1 		$413K Sell
27,428
-11,965
-30% -$182K 0.03% 155
2022
Q4 		$466K Sell
39,393
-13,757
-26% -$99.8K 0.04% 141
2022
Q3 		$315K Sell
53,150
-16,955
-24% -$111K 0.03% 229
2022
Q2 		$298K Buy
70,105
+39,622
+130% +$247K 0.03% 235
2022
Q1 		$290K Buy
30,483
+20,017
+191% +$232K 0.01% 205
2021
Q4 		$199K Buy
+10,466
New +$272K 0.01% 265

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

E Fund Management's TGTX Position: Q2 2026 in Review

E Fund Management reduced its TG Therapeutics (TGTX) stake by 56% in Q2 2026, selling an estimated $477K and leaving 9,040 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #269.

E Fund Management first reported a position in TGTX in Q4 2021 and has held it in 17 quarters since. The position peaked at $756K in Q2 2025. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • E Fund Management held 9,040 shares of TG Therapeutics worth $497K as of Q2 2026.
  • E Fund Management sold 11,666 TG Therapeutics shares in Q2 2026, an estimated $477K.
  • TG Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #269 holding.
  • E Fund Management first reported a position in TG Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • E Fund Management's TG Therapeutics position peaked at $756K in Q2 2025.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.